Administration of agents for the treatment of inflammation
AssigneeElan Pharmaceuticals, Inc.
InventorsJulie Taylor, Theodore A. Yednock
Life of this patent
Estimating the term…
Abstract
A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
Claims11
A method of chronically reducing pathological inflammation in a patient in need thereof comprising chronically administering to the patient natalizumab or an immunologically active fragment thereof that inhibits alpha-4 integrin or inhibits a dimer comprising alpha-4 integrin in a therapeutically effective amount;
- wherein the chronic administration is for a period of at least 6 months,
- the pathological inflammation is caused by multiple sclerosis, and
- the therapeutically effective amount is sufficient to relieve symptoms of multiple sclerosis.
Dependencies are inferred from the claim text.